Table 2.
Disease characteristics and treatment response.
| Patient | Stage∗ | Recurrent | Gross disease | Posttreatment response within the irradiated volume | Months until PD (in or out of irradiated volume) |
|---|---|---|---|---|---|
| 1 | T4N2bM0 | No | Yes | PR | 6.4 (in) |
| 2 | T0N2bM0 | Yes | Yes | CR | 14.7 (in), 16.3 (out) |
| 3 | T0N2bM0R0 | Yes | No | N/A | (Died with NED) |
| 4 | T4N0M0 | Yes | Yes | SD | (Died without PD) |
| 5 | T0N1M0 | Yes | Yes | CR | (Alive with NED) |
| 6 | T4N0M0 | Yes | Yes | SD | (Alive with NED) |
| 7 | T2N2bM0 | No | Yes | PD (during treatment) | 1.7 (in and out) |
| 8 | T0N2bM1 | Yes | Yes | CR | 2.1 (out), 5.0 (in) |
| 9 | T2N2bM0 | Yes | Yes | CR | 4.4 (out) |
| 10 | T4N0M0 | Yes | Yes | SD | 52.2 (in) |
| 11 | T0N3M1 | Yes | Yes | PR | 1.6 (out) |
| 12 | T4N0M0 | No | Yes | PR | 4.4 (out), 4.7 (in) |
Disease status at the start of therapy and investigator assessed response 4–12 weeks after therapy are presented.
*All patients were staged clinically, except patient 3, who was staged pathologically.
PR: partial response, CR: complete response, SD: stable disease, PD: progressive disease, NED: no evidence of disease, IV: irradiated volume, and N/A: not applicable (because patient received adjuvant therapy [no measureable disease for response assessment]).